The popular diabetes and weight-loss drug semaglutide may lower the risk of dementia when taken by Type 2 diabetes patients, new research from the Case Western Reserve School ...

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

Ozempic could cut the risk of dementia by half, a University of Oxford study has suggested. Scientists set out to establish the impact of the weight-loss jab on the brain in the first study of its ...

GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk and potential applications for addiction treatment.

It could also play a role in reducing the risk of dementia.We asked the experts. Odds are you’ve heard of GLP-1 drugs like Ozempic for managing type 2 ... The reduction in food preoccupation ...

“According to the latest figures released by the NHS, dementia diagnosis is at a record high in England. ... Pharmacist cautions against self-medicating with ozempic for dementia risk reduction.

Notably, previous research has determined that diabetes patients are at a greater risk of developing dementia. Patients who took Ozempic also saw an 18% reduction in nicotine dependence compared ...

Results from this study show that there is a direct correlation between the use of anti-obesity medications and testosterone levels,” the study author said.

A study finds a drug known for weight loss may also help to reduce dementia. The study looked at semaglutide, the scientific name for Novo Nordisk's (NVO) (DK:NOVO.B) Ozempic, with the intent of ...

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.